Tenofovir Alafenamide With Fine Needle Aspiration Biopsy in Chronic Hepatitis B:

Inclusion Criteria: * • Age \>18 years * Chronic hepatitis B (HBsAg positive ≥ six months) * HBeAg positive or negative * ALT \>19 for females and \>30 for males (AASLD criteria) * HBV DNA\>4 log IU/mL for HBeAg positive and \>3 log for HBeAg negative patients * No oral antiviral treatment or IFN for ≥6 months * Adequate contraception. For males, at least one method of contraception should be used and for females, a barrier contraception method should be used in combination with one other form of contraception. * Written informed consent Exclusion Criteria: * • Treatment with any investigational drug within 60 days of entry into this protocol * Immune-suppressive treatment within the previous 6 months * History of decompensated cirrhosis (defined as direct (conjugated) * bilirubin \> 1.2 × ULN, * prothrombin time (PT) \> 1.2 × ULN * platelets \< 100,000/mm3 * serum albumin \< 3.5 g/dL * prior history of clinical hepatic decompensation (jaundice in the presence of cirrhosis, ascites, gastric bleeding, oesophageal varices or encephalopathy) * Liver transplantation * Co-infection with hepatitis C virus, hepatitis D virus or HIV * Other significant liver disease: alcoholic liver disease, drug-related liver disease, auto-immune hepatitis, hemochromatosis, Wilson's disease or alpha-1 antitrypsin deficiency * Estimated glomerular filtration rate \<50 mL/min/1.73m2 or any significant renal disease. * Alpha-fetoprotein \> 50 ng/ml * Pregnancy, breast-feeding * Other significant medical illness that might interfere with this study: significant pulmonary dysfunction in previous 6 months, malignancy other than skin basocellular carcinoma in previous 5 years, immunodeficiency syndromes (e.g. HIV positivity, auto-immune diseases, organ transplants other than cornea and hair transplant) * Substance abuse, such as alcohol (≥80 g/day), I.V. drugs and inhaled drugs in past 2 years. Current methadone usage is allowed. * Any other condition which in the opinion of the investigator would make the patient unsuitable for enrolment, or could interfere with the patient participating in and completing the study